Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment

BEIJING, Aug. 27, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr.Jim Wu, Chief Executive Officer of ArkBio, gave an oral presentation entitled"Development of Next Generation Broadly Activ...

2024-08-27 09:00 1682

Fujitsu tackles 'drug loss' in Japan through ecosystem to accelerate digitalization of clinical trials

Fujitsu forms strategic partnership with Paradigm and will provide offerings that leverage the power of AI TOKYO, Aug. 27, 2024 /PRNewswire/ -- Fujitsu today announced that it will begin initiatives to attract global clinical trials toJapan and tackle the 'drug loss' issue by working with pharma...

2024-08-27 08:07 1685

Telix Announces Reorganisation to Deliver on Strategic Priorities

MELBOURNE, Australia, Aug. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiop...

2024-08-27 07:15 1688

Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

- Develops NovaplexTM MPXV/OPXV Assay and NovaplexTM HSV-1&2/VZV/MPXV Assay - Designed to detect four viruses at once using multiplex PCR technology - Utilize dual internal controls to ensure highly reliable test results - Pledges to supply assays meeting the needs of respective countries SE...

2024-08-26 21:00 2052

Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

CStone Reports 2024 Interim Results and Recent Corporate Updates

* Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve atRMB 814 million as of June 30, 2024. * NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in EU, marking the first successful international approval of aChina domestic anti-PD-L1 mAb. ...

2024-08-23 22:20 6716

Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization

SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announced its interim results for the period endingJune 30, 2024 , along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, stated, "In the...

2024-08-23 12:32 3728

Ascentage Pharma Announces 2024 Interim Results

ROCKVILLE, Md. and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced its 2024 interim results. During ...

2024-08-22 23:36 4032

Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities

MELBOURNE, Australia, Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended30 June 2024. All figures are in AU$ unless otherwise stated.[1] H1 2024 financial highlights * Total Group revenue o...

2024-08-22 17:04 1905

Inaugural Process Innovation Asia Pacific to Drive Industry Transformation for South-East Asia's Chemicals and Pharmaceuticals

SINGAPORE, Aug. 22, 2024 /PRNewswire/ -- Organised by Constellar, in partnership with DECHEMA Ausstellungs-GmbH (DECHEMA Exhibitions)[1], the inauguralProcess Innovation Asia Pacific - Powered by ACHEMA (PIA) will be held from19 to 21 November 2024 at Singapore EXPO. The most comprehensive Pr...

2024-08-22 15:30 9287

China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-08-22 08:00 3017

Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption

New Veeva Pulse findings show congresses and early-career experts have the strongest influence on patient outcomes SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outreach maximizes medical affairs te...

2024-08-21 09:00 2697

Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Aug. 20, 2024 /PRNewswire/ -- On August 20, the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) based on the positive results from the pivotal OptiTROP-Lung03 study has been accepted by the Center for Drug Evaluation (CDE)...

2024-08-20 16:32 1561

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

Infinitus Highlights Modernizing Traditional Prescriptions at ICMCM

GUANGZHOU, China, Aug. 20, 2024 /PRNewswire/ -- Recently, the highly-anticipated 23rd International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) took place inHong Kong, bringing together global experts, top researchers and industry leaders in traditional medicine...

2024-08-20 15:09 1551

Infinitus Highlights Modernizing Traditional Prescriptions at ICMCM

Alphamab Oncology Reports 2024 Interim Results and Business Highlights

SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months endedJune 30, 2024 and highlighted recent business progress. Financial Summary * For the six months ended June 30, 2024, we recorded total revenue of RMB ...

2024-08-16 11:18 3323

NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT

HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biop...

2024-08-15 13:43 1788

Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months

* Docquity's Awareness to Advocacy (A2A) Program and strong local distribution network enabled SIT's duo probiotic sales to surpass the market growth rate of 15% * The technology platform boosted SIT's HCP education efforts, more than doubling its reach to 2,000 HCPs within six months and aim...

2024-08-13 10:00 1996

Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE

ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for malignancies, announced today it has been cleared by the Ce...

2024-08-13 09:52 2121

Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial

SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial.This marks the first cell therapy to enter Phase lI trials in both...

2024-08-13 09:00 1775

AI in the IVF Process is the Standard of Care at Virtus Fertility Centre Singapore

The technology developed by Virtus Health's scientists contributes to IVF medicine by shortening the time to a successful pregnancy and improving overall success rates. SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Virtus Fertility Centre Singapore (VFCS) announced that artificial intelligence (AI), ...

2024-08-13 08:44 1781

Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis

HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positive results from its Phase1b clinical study of LNK01004, a skin restricte...

2024-08-13 08:00 1824

1 ... 6 7 8910 11 12 ... 187

Week's Top Stories

DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam

[Picked up by 279 media titles]

2024-11-08 20:11

$DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam$